电邮这篇文章 Experience with the combination of tixagevimab + cilgavimab for pre-exposure prophylaxis of COVID-19 in cancer patients: A retrospective analysis
- 作者: Lyadova M.1,2, Fedorinov D.1,3, Kuzmina E.1, Antonova T.1, Sokolskaya V.1
-
隶属关系:
- Moscow State Budgetary Healthcare Institution "Moscow City Oncological Hospital No.1, Moscow Healthcare Department"
- Novokuznetsk State Institute for the Advanced Training of Doctors – branch of the Russian Medical Academy of Continuous Professional Education
- Russian Medical Academy of Continuous Professional Education
- 期: 卷 25, 编号 3 (2023)
- 页面: 392-396
- 栏目: CLINICAL ONCOLOGY
- URL: https://journals.rcsi.science/1815-1434/article/view/148907
- DOI: https://doi.org/10.26442/18151434.2023.3.202456
- ID: 148907
如何引用文章
全文:
详细
Background. COVID-19 (COrona VIrus Disease 2019) is a serious threat to cancer patients, who are at an increased risk of severe infection complications. Pre-exposure prophylaxis with a combination of monoclonal antibodies, tixagevimab-cilgavimab (Evusheld), has been shown to be effective in preventing COVID-19, reducing hospital admission rate and mortality in immunocompromised individuals.
Aim. To describe the experience of using tixagevimab-cilgavimab for pre-exposure prophylaxis of COVID-19 in the Russian population of patients with solid tumors receiving antitumor drug therapies.
Materials and methods. The retrospective analysis included case histories of 79 patients (57% females and 43% males) with solid tumors treated at the Moscow City Clinical Oncology Hospital No. 1 from October 2022 to June 2023. All patients received tixagevimab-cilgavimab for COVID-19 pre-exposure prophylaxis.
Results. The mean age was 64±11 years (32 to 83 years). Seventy-three percent of patients received cytotoxic therapy, associated with an increased risk of infectious complications, including COVID-19. No immediate or delayed adverse events related to tixagevimab-cilgavimab were reported. During the observation period since the drug injection, 3 (3.8%) new mild cases of COVID-19 were reported.
Conclusion. Tixagevimab-cilgavimab (Evusheld) is safe and effective for pre-exposure prophylaxis of COVID-19 in the Russian population of patients with solid tumors receiving antitumor drug therapy.
作者简介
Marina Lyadova
Moscow State Budgetary Healthcare Institution "Moscow City Oncological Hospital No.1, Moscow Healthcare Department"; Novokuznetsk State Institute for the Advanced Training of Doctors – branch of the Russian Medical Academy of Continuous Professional Education
编辑信件的主要联系方式.
Email: dr.lyadova@gmail.com
ORCID iD: 0000-0002-9558-5579
cand. sci. (med.)
俄罗斯联邦, Moscow; NovokuznetskDenis Fedorinov
Moscow State Budgetary Healthcare Institution "Moscow City Oncological Hospital No.1, Moscow Healthcare Department"; Russian Medical Academy of Continuous Professional Education
Email: deni_fe@mail.ru
ORCID iD: 0000-0001-5516-7367
oncologist
俄罗斯联邦, MoscowEvgeniya Kuzmina
Moscow State Budgetary Healthcare Institution "Moscow City Oncological Hospital No.1, Moscow Healthcare Department"
Email: kuz011@mail.ru
ORCID iD: 0009-0007-2856-5176
chemotherapy department head
俄罗斯联邦, MoscowTatiana Antonova
Moscow State Budgetary Healthcare Institution "Moscow City Oncological Hospital No.1, Moscow Healthcare Department"
Email: tattg@mail.ru
ORCID iD: 0009-0007-6646-7454
chemotherapy day care center head
俄罗斯联邦, MoscowValentina Sokolskaya
Moscow State Budgetary Healthcare Institution "Moscow City Oncological Hospital No.1, Moscow Healthcare Department"
Email: sddv1@yandex.ru
deputy chief doctor
俄罗斯联邦, Moscow参考
- Coronavirus disease (COVID-19). World Health Organization. Available at: https://www.who.int/ru/emergencies/diseases/novel-coronavirus-2019. Accessed: 23.07.2023.
- Worldometers. COVID-19 Coronavirus Pandemic. Available at: https://www.worldometers.info/coronavirus. Accessed: 23.07.2023.
- Статистические данные федерального и региональных оперштабов по борьбе с коронавирусом. Режим доступа: https://стопкоронавирус.рф/information/?ysclid=lo339sal8q714909717. Ссылка активна на 23.07.2023 [Statisticheskie dannye federal'nogo i regional'nykh opershtabov po bor'be s koronavirusom. Available at: https://стопкоронавирус.рф/information/?ysclid=lo339sal8q714909717. Accessed: 23.07.2023 (in Russian)].
- NCCN Updates Recommendations for COVID-19 vaccination with information on bivalent vaccines, children with cancer, and other developments. Available at: https://www.nccn.org/home/news/newsdetails?NewsId=3411. Accessed: 23.07.2023.
- Hall VG, Ferreira VH, Ku T, et al. Randomized trial of a third dose of mRNA-1273 vaccine in transplant recipients. N Engl J Med. 2021;385(13):1244-6. doi: 10.1056/NEJMc2111462
- Cheung MW, Dayam RM, Shapiro JR, et al. Third and fourth vaccine doses broaden and prolong immunity to SARS-CoV-2 in immunocompromised adult patients. J Immunol. 2023;211(3):351-64. doi: 10.4049/jimmunol.2300190
- Информационный бюллетень для медицинских работников: разрешение на применение в период действия чрезвычайной ситуации лекарственного препарата Эвушелд (Evusheld) (тиксагевимаб+цилгавимаб [набор]). Режим доступа: https://hcpinstruction.ru/ Ссылка активна на 16.12.2022 [Informatsionnyi biulleten' dlia meditsinskikh rabotnikov: razreshenie na primenenie v period deistviia chrezvychainoi situatsii lekarstvennogo preparata Evusheld (Evusheld) (tiksagevimab+tsilgavimab [nabor]). Available at: https://hcpinstruction.ru/ Accessed: 16.12.2022 (in Russian)].
- Robbie GJ, Criste R, Dall'acqua WF, et al. A novel investigational Fc-modified humanized monoclonal antibody, motavizumab-YTE, has an extended half-life in healthy adults. Antimicrob Agents Chemother. 2013;57(12):6147-53. doi: 10.1128/AAC.01285-13
- Loo YM, McTamney PM, Arends RH, et al. The SARS-CoV-2 monoclonal antibody combination, AZD7442, is protective in nonhuman primates and has an extended half-life in humans. Sci Transl Med. 2022;14(635):eabl8124. doi: 10.1126/scitranslmed.abl8124
- Al Jurdi A, Morena L, Cote M, et al. Tixagevimab/cilgavimab pre-exposure prophylaxis is associated with lower breakthrough infection risk in vaccinated solid organ transplant recipients during the omicron wave. Am J Transplant. 2022;22(12):3130-6. doi: 10.1111/ajt.17128
- Levin MJ, Ustianowski A, De Wit S, et al. Intramuscular AZD7442 (tixagevimab–cilgavimab) for prevention of COVID-19. N Engl J Med. 2022;386(23):2188-200. doi: 10.1056/NEJMoa2116620
- Montgomery H, Hobbs FDR, Padilla F, et al. Efficacy and safety of intramuscular administration of tixagevimab–cilgavimab for early outpatient treatment of COVID-19 (TACKLE): A phase 3, randomised, double-blind, placebo-controlled trial. Lancet Respir Med. 2022;10(10):985-96. doi: 10.1016/S2213-2600(22)00180-1
- Keam SJ. Tixagevimab+Cilgavimab: First approval. Drugs. 2022;82(9):1001-10. doi: 10.1007/s40265-022-01731-1
- Профилактика, диагностика и лечение новой коронавирусной инфекции: Временные методические рекомендации. Версия 14 от 27.12.2021. Режим доступа: https://static-0.minzdrav.gov.ru/system/attachments/attaches/000/059/041/original/ВМР_COVID-19_V14_27-12-2021.pdf. Ссылка активна на 16.12.2022 [Profilaktika, diagnostika i lechenie novoi koronavirusnoi infektsii: Vremennye metodicheskie rekomendatsii. Versiia 14 ot 27.12.2021. Available at: https://static-0.minzdrav.gov.ru/system/attachments/attaches/000/059/041/original/ВМР_COVID-19_V14_27-12-2021.pdf. Accessed: 16.12.2022 (in Russian)].
- Muka T, Li JJX, Farahani SJ, Ioannidis JPA. An umbrella review of systematic reviews on the impact of the COVID-19 pandemic on cancer prevention and management, and patient needs. Elife. 2023;12:e85679. doi: 10.7554/eLife.85679
- Liang W, Guan W, Chen R, et al. Cancer patients in SARS-CoV-2 infection: A nationwide analysis in China. Lancet Oncol. 2020;21(3):335-7. doi: 10.1016/S1470-2045(20)30096-6
- ElGohary GM, Hashmi S, Styczynski J, et al. The risk and prognosis of COVID-19 infection in cancer patients: A systematic review and meta-analysis. Hematol Oncol Stem Cell Ther. 2022;15(2):45-53. doi: 10.1016/j.hemonc.2020.07.005
- Javadinia SA, Alizadeh K, Mojadadi MS, et al. COVID-19 vaccination in patients with malignancy; A systematic review and meta-analysis of the efficacy and safety. Front Endocrinol (Lausanne). 2022;13:860238. doi: 10.3389/fendo.2022.860238
- Naser M, Bhardwaj PV, Warriach FZ, et al. Real-world effectiveness of prophylactic tixagevimab-cilgavimab monoclonal antibodies on incidence and severity of COVID-19 infection in patients with cancer. J Clin Oncol. 2023;41(16)(Suppl.):e18843. doi: 10.1200/JCO.2023.41.16_suppl.e18843
- Al-Obaidi MM, Gungor AB, Kurtin SE, et al. The prevention of COVID-19 in high-risk patients using tixagevimab–cilgavimab (Evusheld): Real-world experience at a large academic center. Am J Med. 2023;136(1):96-9. doi: 10.1016/j.amjmed.2022.08.019
- Валиахметова Ч.Х., Сираева Э.И., Измайлов А.А. Эффективная профилактика инфекции COVID-19 у онкологических пациентов, получающих противоопухолевую лекарственную терапию (региональный анализ). Современная Онкология. 2023;25(1):111-4 [Valiakhmetova ChKh, Siraeva ER, Izmailov AA. Effective prevention of COVID-19 infection in cancer patients receiving antitumor drug therapy: A regional analysis. Journal of Modern Oncology. 2023;25(1):111-4 (in Russian)]. doi: 10.26442/18151434.2023.1.202170
- First participant dosed in SUPERNOVA Phase I/III trial evaluating AZD5156, a next-generation long-acting antibody combination, for prevention of COVID-19. Available at: https://www.astrazeneca-us.com/media/statements/2022/first-participant-dosed-in-supernova-phase-I-III-trial-evaluating-azd5156-a-next-generation-long-acting-antibody-combination-for-prevention-of-COVID-19.html. Accessed: 03.10.2023.
补充文件
